Industry wants US FDA to reshuffle its priorities on medtech guidelines
This article was originally published in SRA
Executive Summary
US medtech industry association AdvaMed believes that the Food and Drug Administration's annual list of medical device guidelines it plans to issue in this fiscal year misses out some important guidelines that are of high priority to industry because of the lack of transparency/predictability in the areas they would cover1.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.